1. LegoChem Bioscience, Inc.A Leading Chemistry-Based Venture Company COMPANY OVERVIEW

2. Contents Company Overview Business Approach Project Overview Summary

3. Mission Statement ABOUT ABOUT BUSINESS PROJECT SUMMARY LegoChem Biosciences ( “LCB”) is committed to the discovery and development of novel small-molecule drugs employing faster and more efficient ways by combining LegoChemistry and early ADME/T screening platform technologies.

4. Corporate Overview Established in May 2006 (Daeduk Science Town, Daejeon, Korea ) Raised 10.3 billion Korean wons (≈ 10 million US$) since its inception Has built sustainable pipelines in the therapeutic areas of antibiotics, anticoagulants, and oncology The frontrunner, 2nd generation oxazolidinone antibiotics against MRSA is now in regulatory preclinical studies CRO: MPI in USA Novel FXa Inhibitor (anticoagulants) is in regulatory preclinical studies jointly with Green Cross, and is licensed out at the candidate stage to Green Cross in June 2009 Experienced and seasoned executive and scientific management team Preparing IPO to KOSDAQ ABOUT ABOUT BUSINESS PROJECT SUMMARY

5. Management Team ABOUT ABOUT BUSINESS PROJECT SUMMARY Yong Zu Kim, Ph.D Tae Kyo Park, Ph.D Sung Ho Woo, Ph.D Sejin Park Young Lag Cho, Ph.D Ho Young Song, Ph.D HyangSuk Lee Chemistry Sr. Director Project Leader at LGLS 18 journal, 5 patent publications Ph.D. / Chemistry, Yonsei U. CFO / VP GM, R&D Management, 20 yrs at LGLS Co-Founder of LCB, BS/Economy, Korea Univ CEO & President Director of New Drug R&D , 23 yrs at LGLS Co-Founder of LCB, Ph.D. /Chemistry, KAIST Head of Biology / VP Project Leader, 5 yrs at LGLS Co-Founder of LCB, Ph.D. / Microbio, Ohio state CTO & Sr. VP Project Leader, 10 yrs at LGLS Co-Founder of LCB, Ph.D. /Chemistry, MIT Chemistry Director Principal Research at LGLS, Ph.D. / Seoul Nation U. 8 journal, 2 patent publications Biology Director Research Scientist, 11 yrs at LGLS, 4 journal, 10 patent pub. MS /Biochem, Yonsei U.

6. Business Strategy and Model BUSINESS ABOUT BUSINESS PROJECT SUMMARY Model 1 : Independent R&D Internal research & development up to phase 2a License-out at early ~ mid stage (i.e. Oxazolidinone antibiotics, FXa Inhibitor) Model 2 : Collaborative R&D Joint research with strong biology platform up to phase IIa License-out at early ~ mid stage (i.e. Anticancer : HSP90, Mitochondriotropic) Model 3 : Sponsored R&D Sponsored R&D cost from partner up to candidate stage License-out to partner at candidate stage and developed & commercialized by partner (i.e. FVIIa Inhibitor) RISK CORE COMPETENCY Biology Based Med Chem Based

9. LegoChemistry

10. Screening

13. ◆ Early ADME/T serviceGate Decision System Business Model

15. Selectivity

16. Metabolic stability

17. CYP inhibition (DDI)

18. Protein Binding

19. Solubility

21. hERG (Patch Clamp)

22. Single dose Tox

24. Selectivity

25. Metabolic stability

26. CYP inhibition (DDI)

27. Protein Binding

28. Solubility

29. Stability (plasma, solution)

30. PK (t1/2, Vd, CL, AUC)

31. Cytotoxicity

32. BA(rat) > 20%Gate Decision System

33. Platform Technology: LegoChemistry BUSINESS ABOUT BUSINESS PROJECT SUMMARY “New Lego block” molded into existing best chemical structures New Pieces of Lego Block Way of Implementation AREA Disease area with experience Validated (existing) target METHOD Fragment-based approach Multi-component reactions Replacement of existing subgroup Previously unknown Known but not well-explored LCB has more than 20 drug-like unique scaffolds Derived from same Lego Block Successful cases FXa inhibitor (LCB02-0133) Antibiotics (LCB01-0371) C A B Time to candidate : 12 ~ 18 months

35. Singleton Assay

36. 3,800 : 1

37. Over 5 years

38. 5,800 : 1

39. Average 5 years

40. 500 : 1 (or less)

41. Less than 3 yearsR&D Productivity (Candidate for discovery) ☞ Merck Standard The synthesis of core competencies

42. BUSINESS ABOUT BUSINESS PROJECT SUMMARY More than 5 clinical pipelines for new drug by 2012 (Benchmarking: Gilead Science) Initiate pipeline (’06 ~’08) Grow pipeline (’09 ~’11) Sustain pipeline (’12 ~ ) 2 Preclinical candidates, 1 License-out 1 Co-Research contract 3 Clinical pipeline 2 License-out 1 preclinical study/year 5 Clinical pipeline 3 License-out 1 clinical study / year Output Collaboration network Global network Global licensing-out Independent research and development company Manage the process from discovery to development Core Competencies Mid-term Business Plan

43. Research Projects PROJECT ABOUT BUSINESS PROJECT SUMMARY Project Selection Guideline Management’s Previous Experience antibiotics, anticoagulants, anticancer Attractiveness to big pharm unmet medical needs Portfolio Balance (risk management) best-in-class vs. first-in-class Projects Antibiotics Oxazolidinone antibiotics , MDR-TB Gram(-) antibiotics Anticoagulants FXa inhibitor (Partnered with Green Cross) FVIIa inhibitor (Partnered with Hanmi) FXIa inhibitor Anti-cancer HSP 90 (Partnered with BoramPharma) Mitochondriotropic Others DDR2 / HIF-1(Wondonin) / CD-99

44. Project Roadmap PROJECT ABOUT BUSINESS PROJECT SUMMARY (by Green Cross)

45. Discovery Projects: Summary PROJECT ABOUT BUSINESS PROJECT SUMMARY

46. Scope of IP landscape ABOUT BUSINESS PROJECT SUMMARY SUMMARY FXa inhibitors FVIIa inhibitors Anticancer Patent to be published + Antibiotics

47. Summary of LCB ABOUT BUSINESS PROJECT SUMMARY SUMMARY Experienced and skilled researchers Hands on experience on driving project from early lead discovery to FDA approval Established experience and network for licensing-out, collaboration, and negotiation with multi-national pharmaceutical companies Excellence of Core Technology Unique distinction of LegoChemistry scaffold approach Ability to generate consistent project pipeline ( >20 novel Scaffold, 25,000 compounds focused library) Systematic research plan via Gate Decision System Established guidelines for key stage decision to distinguish between ‘good’ and ‘bad’ drugs Implementing ‘fast track’ new drug discovery Passion for new drug development New drug discovery is the only way to survive! “Establishing a new drug pipeline is dependent on securing drug-like leads, and LCB has the necessary technology, system and passion to deliver it.”

48. Contact LegoChem Biosciences, Inc. Daejeon Bio Venture Town, 461-8 Jeonmin-dong, Yuseong-gu, Daejeon, 305-811, South Korea http://www.legochembio.com/ CONTACT: Sung-Ho Woo, Ph.D. Biology Director & Senior VP [Tel] +82-42-861-0688 [Fax] +82-42-861-0689 E-mail: sungwoo@legochembio.com Request for more materials ONE PAGE: Brief outline of a project in a one page PDF file PROJECT PPT: Detailed version of a project description and a 5 MIN VIDEO presentation COMPANY DOC: Comprehensive overview of company’s business plan and project description in written format.